Clinical Edge Journal Scan

Obesity is a risk factor for recurrence in aromatase inhibitor-treated HR+ BC


 

Key clinical point: Obesity increased the risk for recurrence in postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were treated with aromatase inhibitors (AI).

Major finding: Among patients with AI-treated HR+ BC, the risk for BC recurrence was significantly higher in those with obesity ( adjusted hazard ratio [aHR] 1.18; 95% CI 1.01-1.37 ) and severe obesity ( aHR 1.32; 95% CI 1.08-1.62 ) than in those with a healthy weight.

Study details: Findings are from a nationwide cohort study including 13,230 postmenopausal women with stages I-III HR+ BC who received AI.

Disclosures: This study was supported by the Jeppe Juhl Memorial Foundation, Denmark, and other Danish sources. Jensen MR declared receiving from Novartis meeting expenses and personal fees unrelated to this study.

Source: Harborg S et al. Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors. JAMA Netw Open. 2023;6(10):e2337780 (Oct 13). doi: 10.1001/jamanetworkopen.2023.37780

Recommended Reading

ICIs improve pCR rates in early ER+/HER2– breast cancer
MDedge Hematology and Oncology
The sobering facts about alcohol and cancer
MDedge Hematology and Oncology
Dato-DXd trumps chemo in advanced HR+/HER2– breast cancer
MDedge Hematology and Oncology
Commentary: Axillary Surgery, PM2.5, and Treatment With Tucatinib in Breast Cancer, November 2023
MDedge Hematology and Oncology
Omitting surgery may be safe in early BC after neoadjuvant pCR
MDedge Hematology and Oncology
T-DXd benefits persist for HER2-low breast cancer
MDedge Hematology and Oncology
Low vitamin D linked to paclitaxel-induced peripheral neuropathy
MDedge Hematology and Oncology
Particulate pollution increases the risk for breast cancer
MDedge Hematology and Oncology
An 88-year-old Black woman presented with 3 months duration of asymptomatic, violaceous patches on the left breast
MDedge Hematology and Oncology
Highlights in Early Breast Cancer From ESMO 2023
MDedge Hematology and Oncology